Werth Lab

The Autoimmune Skin Disease Unit @Penn
Lab of Dr. Victoria Werth
#dermatomyositis #lupus #blistering

Managed by lab members

[Werth Lab @werthlab]

Excited to share our research with the @NIH AMP AIM on plasmacytoid dendritic cells at #PhillyDerm society meeting! Congrats to Sarah June for taking first place!

[Lupus Research @LupusResearch]

New #ClinicalTrial update:
@Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the litifilimab significantly reduced skin disease activity in cutaneous lupus erythematosus (CLE).
Learn more: https://t.co/LzOFl684Ut
#LupusResearch #Lupus

[NEJM @NEJM]

Presented at #AAD2026:

In the VALOR trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose. Full trial results: https://t.co/7XyzxO1mkl

@AADmember

[Werth Lab @werthlab]

We’re at the late breaking session @AADskin #AAD2026 sharing the 24-week results for #litifilimab for cutaneous #lupus

[Werth Lab @werthlab]

We’re at @MedDermSoc #MDS2026! Excited to share our data on infection risk in #pemphigus by Sarini Saksena @sarini_saksena from our group. @healourskin

[Lupus Research @LupusResearch]

Noted dermatologist Victoria Werth speaks to @TheLupusForum about the importance of the U.S. FDA accepting CLASI as a tool to measure the effectiveness of potential treatments for cutaneous lupus – a debilitating type of lupus that targets the skin for which there are no specific treatments.

Dr. Werth credits this acceptance to the work of the public-private partnership — the Lupus Accelerating Breakthroughs Consortium — convened by the LRA with the FDA to advance development of new treatments for lupus.

Check it out below ⬇️
https://t.co/FXXCEdKsWx

#lupus #lupusresearch

[Werth Lab @werthlab]

The effect of #belimumab on mucocutaneous and vasculitis manifestations in patients with systemic #lupus erythematosus: A large pooled post hoc analysis @SageJournals https://t.co/Dce5nvx7rM

[Werth Lab @werthlab]

Erythema and scale in cutaneous #lupus erythematosus significantly impacts patient quality of life #QoL and disease course impression @BrJDermatol https://t.co/e5TXeSA661

[Werth Lab @werthlab]

The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic #lupus erythematosus: A large pooled post hoc analysis @SageJournals https://t.co/Rxs87mzGrg

[Werth Lab @werthlab]

Clinical Images: Subcutaneous panniculitis-like T cell lymphoma @ACR_Journals
https://t.co/xsOOChIGD2

[Werth Lab @werthlab]

Modern therapy of patients with #lupus erythematosus must include appropriate management of their heightened rates of atherosclerotic cardiovascular events: a literature update @LaisGomesDerm @Lupus_SM https://t.co/LwM4HT2FMw

[Werth Lab @werthlab]

Now online in @theJIDJournal by @pedalonbeauty and others from our lab! In this study, we looked at the effects of Lenabasum, a #cannabinoid receptor 2 agonist for #dermatomyositis. https://t.co/BMtveeUFRx

[Healio Dermatology @HealioDerm]

🔎 Victoria P. Werth, MD, discussed the link between herbal intake and lower rates of #autoantibodies in people with #dermatomyositis.

https://t.co/Sm5yJs70Hd

@JAMADerm @werthlab @PennMedicine @GoHealio

[Healio Dermatology @HealioDerm]

✅ Autoantibody positivity rates were lower in patients with #dermatomyositis who used immunostimulatory #herbs, including:

- alfalfa
- ashwagandha
- chlorella
- and more,

before disease onset, according to a @JAMADerm study.

https://t.co/Sm5yJs70Hd

@werthlab @PennMedicine

[Werth Lab @werthlab]

Our latest article by, Pain and itch in cutaneous #lupus erythematosus, is now available online in @JAADjournals an important study to understand impact of #CLE related #pain and #itch on patient quality of life #QoL! https://t.co/dlWvKGqClN

[ACR_Journals @ACR_Journals]

Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus

📄 Read the paper: https://t.co/56eOK86lmn

ℹ️ See additional content and resources on this guideline at https://t.co/PVEyOkY14w

[Lupus Hub @lupus_hub]

CONGRESS | #ACR25 | PRESENTATION
Victoria Werth, University of Pennsylvania, discusses applying the 2025 ACR guidelines to the treatment and management of cutaneous lupus; highlighting the considerations for clinical practice using two patient case examples. Key recommendations were outlined for cutaneous lupus erythematosus (CLE), bullous LE, chilblain lupus and vasculitis.

Follow our live feed for more updates: https://t.co/KatJ2k2Nf7

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lupus #MedEd #MedicalCongress #RheumTwitter @werthlab @Penn

[Werth Lab @werthlab]

We’re at #ACR2025 !! #rheumtwitter

[Werth Lab @werthlab]

Another busy rheum-derm clinic in the books with many residents, researchers, and students! We’re looking forward to seeing everyone at @RheumDermSoc meeting and #ACR2025 @ACRheum

[MIHRA @MIHRAfoundation]

This w'end #MIHRA leadership in Dallas #MyoCon. @werthlab rec'd Science Award‼️ Intro'd by past recipient& MIHRA board member @HeleneAlex1969 MIHRA Mayo board members FloranneErnste & @ElieNaddaf3 rec'd Care Award‼️ Creating a World Where We Cure Myositis Together ✨️❤️ 🧡💛✨️